RefleXion is developing a biology-guided radiotherapy (BgRT)* machine that is the first to utilize the cancer’s biology itself to guide radiation delivery, even in tumors that are moving. The technology uses positron emission tomography (PET) to guide personalized radiotherapy. RefleXion’s platform enables a leap forward in the ongoing goal of conventional radiotherapy to manage motion, and potentially diminish radiation toxicity, making it feasible to one day provide more options for patients with advanced stage cancer.
Currently, the RefleXion machine is cleared by the U.S. Food and Drug Administration (FDA) for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).
*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to Investigational use.